06bce6743d40c7eb80af7caf2f26f619

ANTI-DIA (DI1)

BIOCIENTIFICA LTDA.·III·Colombia INVIMA·Expires May 23, 2029
Device classification
Risk class / Clase de Riesgo
III
Product type (Spanish)
REACTIVO DIAGNOSTICO
Product type (English)
DIAGNOSTIC REAGENT
Registration information
Analysis ID
06bce6743d40c7eb80af7caf2f26f619
Expire date
May 23, 2029
Authorized company / Fabricante
Name (Spanish)
BIOCIENTIFICA LTDA.
Name (English)
BIOSCIENTIFIC LTDA.
Product use / Uso del Producto
Spanish

LOS ANTISUEROS REACTIVOS DE COOMBS SON REACTIVOS_x000D_ POLICLONALES PARA LA IDENTIFICACIÓN DE ANTÍGENOS_x000D_ ERITROCITARIOS DE DIVERSOS SISTEMAS DE GRUPOS _x000D_ SANGUÍNEOS: SISTEMA KELL (K, KPA B, KPA, JSA, JSB), _x000D_ SISTEMA DUFFY (FYA FYB), SISTEMA LUTHERAN (LUA), _x000D_ SISTEMA KIDD (JKB), SISTEMA XG (XGA), SISTEMA DIEGO _x000D_ (DIA WRA). ESTÁN INDICADOS PARA LA EJECUCIÓN DEL _x000D_ TEST INDIRECTO DE ANTIGLOBULINA HUMANA EN TUBO DE_x000D_ ENSAYO.

English

COOMBS REACTIVE ANTISERA ARE REACTIVOS_x000D_ POLYCLONAL FOR THE IDENTIFICATION OF ANTÍGENOS_x000D_ ERYTHROCYTES FROM VARIOUS GROUP SYSTEMS _x000D_ BLOOD: KELL SYSTEM (K, KPA B, KPA, JSA, JSB), _x000D_ DUFFY SYSTEM (FYA FYB), LUTHERAN SYSTEM (LUA), _x000D_ KIDD SYSTEM (JKB), XG SYSTEM (XGA), DIEGO SYSTEM _x000D_ (WRA DAY). THEY ARE INDICATED FOR THE EXECUTION OF THE _x000D_ INDIRECT HUMAN ANTIGLOBULIN TEST IN DE_x000D_ TUBE PRACTICE.

About this record

Access comprehensive regulatory information for ANTI-DIA (DI1) (ANTI-DIA (DI1)) in the Colombia medical device market through Pure Global AI's free database. This III medical device is registered under INVIMA analysis ID 06bce6743d40c7eb80af7caf2f26f619 and manufactured by BIOCIENTIFICA LTDA.. The device was registered on May 23, 2029.

This page provides complete registration details including product type (DIAGNOSTIC REAGENT), authorised information, and regulatory compliance data from the official Colombia INVIMA medical device database. Pure Global AI offers free access to Colombia's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate INVIMA regulations efficiently.